I-06 Raouf EL Cheikh
A New Protocol for the Administration of Etoposide–Cisplatin in Metastatic Small Cell Lung Cancer
Wednesday 10:20-11:40 |
I-09 Eric Fernandez
Modelling and translating head and neck radiation therapy on all three levels: in vitro, in vivo and clinical
Wednesday 10:20-11:40 |
I-16 María García-Cremades
A comparison of different model-based approaches to scale preclinical to clinical tumour growth inhibition in gemcitabine-treated pancreatic cancer
Wednesday 10:20-11:40 |
I-20 Ekaterina Gibiansky
Population Pharmacokinetic of Obinutuzumab (GA101) in Patients with Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), Other Indolent Non-Hodgkin’s Lymphoma (iNHL) Subtypes, Diffuse Large B-cell Lymphoma (DLBCL), and Mantle Cell Lymphoma (MCL)
Wednesday 10:20-11:40 |
I-28 Sebastiaan Goulooze
Monte-Carlo simulations of sunitinib therapeutic drug monitoring in patients with gastrointestinal stromal tumours.
Wednesday 10:20-11:40 |
I-30 Joachim Grevel
Exposure-response analysis for efficacy and safety of sorafenib in patients with differentiated thyroid carcinoma (DTC)
Wednesday 10:20-11:40 |
I-31 Monia Guidi
Population pharmacokinetic analysis of the IAPs antagonist Debio 1143 and its major metabolite in oncologic patients
Wednesday 10:20-11:40 |
I-37 Fangran Hao
Pharmacokinetic-pharmacodynamic modeling of the anti-tumor effect of sunitinib combined with dopamine in the human non-small cell lung cancer xenograft
Wednesday 10:20-11:40 |
I-40 Andrea Henrich
PK/PD model extension to characterise bone marrow exhaustion in cancer patient making use of a prior paclitaxel PK model
Wednesday 10:20-11:40 |
I-42 Jennifer Hibma
Population Pharmacokinetic/Pharmacodynamic Evaluation of the Effect of Inotuzumab Ozogamicin on QT Intervals in ALL and NHL Patients
Wednesday 10:20-11:40 |
I-50 Diane-Charlotte Imbs
Modeling and simulation for improving the efficacy of the combination between antiangiogenic and chemotherapy in Non Small Cell Lung Cancer
Wednesday 10:20-11:40 |
I-59 Matts Kågedal
Selection of exposure metrics AUC, Cmax or Cmin in exposure response analyses – a simulation study.
Wednesday 10:20-11:40 |
I-63 Lena Klopp-Schulze
Tamoxifen and endoxifen pharmacokinetics: Exploration of differences in model performance using simulations
Wednesday 10:20-11:40 |
II-04 Maurice Ahsman
Modelling and simulation of oral GnRH Antagonist TAK-385 and testosterone-lowering response in Prostate Cancer Patients to Optimize Trial Design and Dose Selection
Wednesday 15:10-16:30 |
II-05 Sihem Bihorel
A plateform PK/PD Model for Antibody Drug Conjugates Induced Myelosuppression
Wednesday 15:10-16:30 |
II-27 Jennifer Bonner
Building of virtual geriatric cancer populations for physiologically-based pharmacokinetic modelling and simulation in cancer patients greater than 70 years of age
Wednesday 15:10-16:30 |
II-36 Tim Cardilin
Extending the Tumor Static Concentration curve to average doses – a combination therapy example using radiation therapy
Wednesday 15:10-16:30 |
II-40 Pascal Chanu
A model to predict progression free survival in patients with previously untreated HER2-positive progressive or recurrent locally advanced or metastatic breast cancer based on tumor growth inhibition metrics
Wednesday 15:10-16:30 |
II-43 Christophe Chassagnole
Modelling the Emergence of Resistance to Chemotherapeutics with Virtual Tumour
Wednesday 15:10-16:30 |
II-48 Laurent Claret
A model to predict progression-free survival in patients with renal cell carcinoma based on week 8 change in tumor size
Wednesday 15:10-16:30 |
II-55 Damien Cronier
PK/PD Modeling of Overall and Progression-Free Survival in Advanced Soft Tissue Sarcoma Patients Treated With Olaratumab in Combination with Doxorubicin.
Wednesday 15:10-16:30 |
II-61 Bernardo de Miguel Lillo
Modeling the dynamics of alanine aminotransferase in advanced cancer patients treated with kahalalide F
Wednesday 15:10-16:30 |
II-63 Aurelia de Vries Schultink
Pharmacokinetics of MCLA-128 in cynomolgus monkeys and extrapolation to humans to support selection of first-in-human dose
Wednesday 15:10-16:30 |
II-67 Laurence Del Frari
Predicting human pharmacokinetics of monoclonal antibodies by allometric translation from preclinical data: a case study
Wednesday 15:10-16:30 |
III-09 Sreenath M Krishnan
Population modeling of uni- and three- dimensional and density-based tumor measurements in gastro-intestinal stromal tumor (GIST) patients treated with imatinib
Thursday 10:05-11:30 |
III-21 Litaty Céphanoée Mbatchi
Pharmacokinetics modelling of temsirolimus and its active metabolite
Thursday 10:05-11:30 |
III-23 Evgeny Metelkin
Development of immune responce template forsystems pharmacology modeling of immunotherapy in oncology
Thursday 10:05-11:30 |
III-44 Zinnia Parra-Guillen
Pharmacokinetic analysis of midazolam and caffeine as probe drugs for cytochrome phenotyping in erlotinib treatment
Thursday 10:05-11:30 |
III-47 Belén Pérez Solans
Markov model for tumor shrinkage effects of combination therapy in non-metastatic gastric cancer patients
Thursday 10:05-11:30 |
III-56 Philippe Pierrillas
From mouse to human: comparison of interspecies translational strategies using integrative semi-mechanistic PK-PD models and PBPK-PD modeling to forecast efficacious clinical dose
Thursday 10:05-11:30 |
IV-05 Emilie Schindler
PK-PD modeling of VEGF, sVEGFR-1, sVEGFR-2, sVEGFR-3 and tumor size as predictors of overall survival in axitinib-treated metastatic renal cell carcinoma (mRCC) patients
Thursday 14:40-16:00 |
IV-09 Kevin Smart
Modeling tumor size time course in platinum resistant/refractory ovarian cancer patients treated with vanucizumab
Thursday 14:40-16:00 |
IV-16 Oleg Stepanov
A quantitative systems pharmacology model to explore combination efficacy of immuno-oncology compounds: Effects of CXCR2 and PD-1 inhibitions
Thursday 14:40-16:00 |
IV-24 Rob ter Heine
The influence of erythrocyte accumulation on everolimus pharmacokinetics and pharmacodynamics in cancer patients
Thursday 14:40-16:00 |
IV-27 Hoai-Thu Thai
Model-based drug development to support isatuximab dosing regimen selection in Phase II multiple myeloma patients
Thursday 14:40-16:00 |
IV-29 Yingying Tian
Population pharmacokinetic analysis of everolimus in patients with solid tumors
Thursday 14:40-16:00 |
IV-33 Elena Tosca
Evaluation of a PK/PD DEB-based model for tumor-in-host growth kinetics under anticancer treatment
Thursday 14:40-16:00 |
IV-34 Mira Tout
Rituximab target-mediated elimination is influenced by both baseline antigenic burden and FCGR3A polymorphism in chronic lymphocytic leukemia
Thursday 14:40-16:00 |
IV-55 Siyuan Wang
An integrated PK/PD model to link the frequency of cancer-stem-like cells to tumor volume for sunitinib combined with dopamine in the treatment of drug-resistant breast cancer
Thursday 14:40-16:00 |
IV-64 Jan-Georg Wojtyniak
A cancer cell cycle model to predict effects of combination therapy and different dosing schedules on cell cycle, tumor growth and therapy outcome
Thursday 14:40-16:00 |
IV-70 Huixin Yu
Development of a pharmacokinetic model for pazopanib – a tyrosine kinase inhibitor used for the treatment of solid tumours
Thursday 14:40-16:00 |
IV-76 Li Zhu
Population Pharmacokinetic Modeling of Ulocuplumab, an anti-CXCR4 Monoclonal Antibody in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Multiple Myeloma
Thursday 14:40-16:00 |
